Ambrx Biopharma Inc
AMAM
AMAM was delisted on the 6th of March, 2024.
15 hedge funds and large institutions have $165M invested in Ambrx Biopharma Inc in 2021 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 6 reducing their positions, and 7 closing their positions.
4.34% less ownership
Funds ownership: 39.85% → 35.51% (-4.3%)
25% less funds holding
Funds holding: 20 → 15 (-5)
38% less capital invested
Capital invested by funds: $266M → $165M (-$101M)
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
83% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 6
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.61M |
| 2 |
Morgan Stanley
New York
|
+$50.4K |
| 3 |
MIFH
Migdal Insurance & Financial Holdings
Petach Tikva,
Israel
|
+$3.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
-$22.9M |
| 2 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$2.16M |
| 3 |
OCA
Octagon Capital Advisors
New York
|
-$1.8M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$1.37M |
| 5 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$717K |
AMAM Hedge Fund Activity: Q3 2021 in Review
15 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Ambrx Biopharma Inc (AMAM) for Q3 2021, worth a combined $165M — down 38% from $266M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of AMAM and 2 opened new positions — a net loss of 5 holders — while 6 trimmed existing stakes and 1 added.
The largest buyer was Fidelity Investments, adding an estimated $1.61M. The largest seller was Suvretta Capital Management, exiting entirely with an estimated $22.9M sold.
- 15 institutional investors held Ambrx Biopharma Inc (AMAM) as of Q3 2021, down from 20 in Q2 2021.
- Funds reported $165M of Ambrx Biopharma Inc stock for Q3 2021, down 38% quarter-over-quarter.
- 2 funds opened new Ambrx Biopharma Inc positions in Q3 2021 and 7 closed out, a net change of -5 holders.
- The largest Ambrx Biopharma Inc buyer in Q3 2021 was Fidelity Investments, an estimated $1.61M added.
- The largest Ambrx Biopharma Inc seller in Q3 2021 was Suvretta Capital Management, an estimated $22.9M sold.
Based on aggregated 13F filings for Q3 2021.